ArticleJournal of clinical medicine2020
The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Proton pump inhibitor use: systematic review of global trends and practices.European journal of clinical pharmacology · 2023Pooled it
- Preoperative Deprescribing for Medical Optimization of Older Adults Undergoing Surgery: A Systematic Review.Journal of the American Medical Directors Association · 2022Pooled it
- Polypharmacy and Hyperpolypharmacy in Older Individuals with Parkinson's Disease: A Systematic Review and Meta-Analysis.Gerontology · 2022Pooled it
- Electronic Decision Support for Deprescribing in Older Adults Living in Long-Term Care: A Stepped-Wedge Cluster Randomized Trial.JAMA network open · 2025Trial
- Characterising pharmacist interventions from person-centred medicines reviews in general practice settings.Exploratory research in clinical and social pharmacy · 2026Article
- Nonvariceal Upper GI Bleeding in Established Users of Proton-Pump Inhibitors: Higher Incidence But Better Outcomes.Clinical and translational gastroenterology · 2026Observational
- A Clinical Medication Review Focused on Deprescribing in Older Patients With Hyperpolypharmacy: A Mixed-Methods Feasibility Study.Basic & clinical pharmacology & toxicology · 2026Article
- Duration of anticholinergic burden and polypharmacy and the risk of fractures in older Korean adults: a nationwide cohort study.BMC geriatrics · 2026Article
- Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study.Journal of general internal medicine · 2024Observational
- Prevalence of Polypharmacy of Older People in a Large Brazilian Urban Center and its Associated Factors.International journal of environmental research and public health · 2023Article
- Drug-Drug Interactions and the Risk of Emergency Hospitalizations: A Nationwide Population-Based Study.Drug safety · 2023Article
- Potentially inappropriate medication among older patients with diabetic kidney disease.Frontiers in pharmacology · 2023Article
- Pharmacotherapy Problems in Best Possible Medication History of Hospital Admission in the Elderly.Pharmacy (Basel, Switzerland) · 2022Article
- Potentially inappropriate medication use by level of polypharmacy among US Veterans 49-64 and 65-70 years old.Pharmacoepidemiology and drug safety · 2022Article
- Observational
- Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases-STOPP/START-based study.Frontiers in public health · 2022Article
- Patient- and Prescriber-Related Factors Associated with Potentially Inappropriate Medications and Drug-Drug Interactions in Older Adults.Journal of clinical medicine · 2021Article
- Risk of Hospital Readmission among Older Patients Discharged from the Rehabilitation Unit in a Rural Community Hospital: A Retrospective Cohort Study.Journal of clinical medicine · 2021Article
- Potentially Inappropriate Medication and Associated Factors Among Older Patients with Chronic Coronary Syndrome at Hospital Discharge in Beijing, China.Clinical interventions in aging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using data from the French National Insurance databases. The study period was from 1 January 2016 to 31 December 2016. Chronic drug use was defined as uninterrupted daily use lasting ≥6 months. Chronic polypharmacy was defined as the chronic use of ≥5 medications, and chronic hyperpolypharmacy as the chronic use of ≥10 medications. For individuals aged ≥65 (older adults), PIMs were defined according to the Beers and Laroche lists, and for individuals aged 45-64 years (middle-aged) PIMs were defined according to the PROMPT (Prescribing Optimally in Middle-aged People's Treatments) list. Among individuals with chronic polypharmacy, 4009 (46.2%) middle-aged and 18,036 (64.8%) older adults had at least one chronic PIM. Among individuals with chronic hyperpolypharmacy, these figures were, respectively, 570 (75.0%) and 2544 (88.7%). The most frequent chronic PIM were proton pump inhibitors (43.4% of older adults with chronic polypharmacy), short-acting benzodiazepines (older adults: 13.7%; middle-aged: 16.1%), hypnotics (6.1%; 7.4%), and long-acting sulfonylureas (3.9%; 12.3%). The burden of chronic PIM appeared to be very high in our study, concerning almost half of middle-aged adults and two-thirds of older adults with chronic polypharmacy. Deprescribing interventions in polypharmacy should primarily target proton pump inhibitors and hypnotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.